Key Takeaways
Why Sensitivity Is Not Just a Number
The limit of detection (LOD) for an ELISA is formally defined as the concentration of analyte producing a signal equal to the mean of the zero standard plus two (or three, depending on convention) standard deviations. Vendors may alternatively report the lower limit of quantification (LLOQ) — the lowest concentration that can be accurately quantified with a predetermined precision and accuracy — and these values are not interchangeable.
For cytokine measurement in healthy donor serum, where physiological IL-6 levels often fall below 3 pg/mL, a kit claiming 1 pg/mL sensitivity under optimised laboratory conditions may yield unreliable data if matrix effects are not accounted for. Endogenous interfering substances, haemolysis, and protein binding all alter assay performance relative to the aqueous standard curve.
Figure 1. Representative 4-parameter logistic (4PL) standard curve for Human IL-6, showing LOD (0.39 pg/mL) and LLOQ (1.56 pg/mL).
Spike-Recovery & Matrix Validation
Spike-recovery experiments involve adding a known concentration of recombinant analyte to your specific sample matrix (serum, plasma, tissue lysate) and then measuring the recovered concentration. Acceptable recovery is generally defined as 80–120% relative to the spiked concentration, as per FDA Bioanalytical Method Validation guidance.
Parallelism assessment — serially diluting a high-concentration sample and comparing the dilution curve to the standard curve — confirms that the signal is proportionally inhibited by dilution, evidence that no matrix-specific interference is operating at lower concentrations.
Cross-Reactivity & Antibody Specificity
For sandwich ELISA formats, specificity is determined by the epitope pairing of capture and detection antibodies. A well-designed pair targeting non-overlapping, sterically distinct epitopes on the same protein reduces off-target binding while maintaining high-affinity capture. The table below shows the cross-reactivity profile for the eBioHippo Human IL-6 ELISA Kit (EHH-ELI-00231).
| Analyte | Concentration Tested | Signal (OD₄₅₀) | Cross-Reactivity |
|---|---|---|---|
| IL-6 (Human) — target | 100 pg/mL | 2.14 | 100% (reference) |
| IL-6 (Mouse) | 2,000 pg/mL | 0.09 | <2% |
| IL-8 (Human) | 2,000 pg/mL | 0.04 | <0.5% |
| IL-11 (Human) | 2,000 pg/mL | 0.03 | <0.5% |
| IL-31 (Human) | 2,000 pg/mL | 0.04 | <0.5% |
| TNF-α (Human) | 2,000 pg/mL | 0.03 | <0.5% |
| IFN-γ (Human) | 2,000 pg/mL | 0.04 | <0.5% |
Figure 2. Cross-reactivity of the Human IL-6 ELISA Kit (EHH-ELI-00231) against structurally related human and murine cytokines at 2,000 pg/mL.
Choosing the Right ELISA Format
Direct ELISAs are fast but have poor sensitivity and specificity — the antigen is coated directly onto the plate, and any protein in the sample competes for binding. Indirect ELISAs improve sensitivity through signal amplification but are prone to non-specific binding. Sandwich ELISAs — the format used in all eBioHippo cytokine kits — provide the best combination of sensitivity, specificity, and dynamic range for complex biological matrices.
References
- Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, ELISA. J Immunol. 1972;109(1):129–135.
- Tighe PJ, Ryder RR, Todd I, Fairclough LC. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl. 2015;9(3–4):406–422.
- US Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. May 2018.
- ICH Harmonised Guideline M10: Bioanalytical Method Validation and Study Sample Analysis. May 2022.
